AbbVie Pledges $100 Billion in US Investment Over 10 Years, Wins Three-Year Exemption From Tariffs and Drug Pricing Mandates

AbbVie announced a voluntary agreement with the Trump administration on January 12, 2026 to invest $100 billion in US research, manufacturing, and capital over 10 years in exchange for a three-year exemption from Trump-era pharmaceutical tariffs and drug pricing mandates. AbbVie also agreed to provide Medicaid low-price access and join the TrumpRx direct-to-patient program covering HUMIRA, SYNTHROID, and other top-selling drugs. The deal followed Trump's "Most Favored Nation" drug pricing campaign, part of a broader White House pressure campaign converting pharma industry exemptions into investment pledges.